Clinical trials of patients with multiple sclerosis (MS) have produced inconsistent results for the profi le of cytokine secretion in serum and cerebrospinal fl uid in patients with multiple sclerosis during periods of relapse and remission. Epidemiological and clinical observations data reveal an association of the changes in vitamin D serum concentration with the risk of developing MS. AIM: To evaluate changes in serum concentrations of 25(OH)D, IL17, IFN-gamma, TGFβ1, IL4, IL10 in relapse and remission and their correlation with the severity of disability. PATIENTS AND METHODS: Fifty-three persons (30 clinically healthy controls and 23 patients with relapsing-remitting multiple sclerosis) living between 41° and 42° northern latitude were registered during the astronomical winter period (October 2012-May 2013. Patients were diagnosed according to Mc Donald 2010 criteria. The degree of neurological defi cit was assessed by EDSS. Serum concentrations of 25(OH)D (nmol/l) and cytokines (pg/ml) were tested by ELISA -once for controls and twice for patients (during relapse and remission). RESULTS: In the studied population average levels of 25(OH)D were close to insuffi ciency, most pronounced in patients in relapse, as differences were not statistically signifi cant. A reverse correlation was found between the levels of 25(OH)D and the defi cit in relapse and remission. Concentrations of TGFβ1 signifi cantly increased in remission compared with exacerbation and controls. Serum level of IL4 was signifi cantly lower in relapse compared with controls. In remission there was a marked tendency of increase compared with exacerbation. During clinical improvement IL17 and IFN-gamma tended to decrease compared to the average levels in relapse. In both periods, the average concentrations of IFN-gamma in patients were signifi cantly lower compared with controls. No statistically signifi cant differences were found comparing cytokine changes with those of 25(OH)D and defi cit. CONCLUSION: Persistent cytokine imbalance in patients compared with controls is a marker for Th1-mediated CNS demyelination. Anti-infl ammatory TGFβ1, IL4 are indicators of immune response intensity. The defi cit severity does not depend on changes of the tested cytokines, but correlates with 25(OH)D levels during periods of relapse and remission. SA -однократно в контрольной группе и двукратно среди пациентов (во время приступа и ремиссии). РЕЗУЛЬТАТЫ: У обследованного контингента средние уровни 25(ОН)D находятся на пороге недостаточности, сильнее всего выраженной среди больных в состоянии приступа, без наличия статистически значимых различий. Установлена обратная корреляционная зависимость между уровнями дефицита 25(OH)D во время приступа и ремиссии (r приступ = -0.593, р = 0.03; r ремиссия = -0.46, p = 0.024). Во время ремиссии значительно возрастают концентрации TGFβ1 по сравнению с экзацербацией (p = 0,0001) и с контрольной группой (p = 0.001). Сывороточный уровень IL4 является сигнификантно более низким во время приступа по сравнению с контрольной группой (p = 0.049). Во время ремиссии наблюдается выраженная тенденция повышения по сравнению с экзацербацией (p = 0.054). В период клинического улучшения наблюдается тенденция понижения уровней IL17, IFN-gamma по сравнению со средними уровнями в период приступа. Во время обоих периодов средние концентрации IFN-gamma у пациентов являются сигнификантно более низкими по сравнению с контрольной группой (p = 0.036, p = 0.05). При сопоставлении изменений уровня цитокинов с изменениями уровня дефицита 25(ОН)D не установлены статистически значимые взаимосвязи. ЗАКЛЮЧЕНИЕ: Персистирующий цитокиновый дисбаланс у пациентов по сравнению с контрольной группой является маркером Th1, вызванной демиелинизацией в ЦНС. Антивоспалительные цитокины TGFβ1, IL4 являются показателями интенсивности иммунной реакции. Тяжесть дефицита не зависит от изменений исследуемых цитокинов, но коррелирует с уровнями 25(OH)D во время периодов приступа и ремиссии. Research on the causal link between the dynamics in serum concentrations of immune parameters, vitamin D levels and clinical indicators of disease activity will clarify aspects of the mechanism of the immune process so that the therapeutic control of disturbed immune regulation is optimized.
the risk of developing MS, and with the phases of relapse and remission. 8, 11 An indicator of vitamin D status in the body is the serum concentration of 25 hydroxyvitamin D /25(OH)D/, which correlates with the biologically active metabolite having properties of the hormone 1,25 dihydroxyvitamin D /1,25(OH)2D/. 8 Data obtained in vitro support the hypothesis of suppressive effect of 1,25(OH)2D on the synthesis of the pro-infl ammatory cytokines IFN-gamma, IL17, IL2, of the induction of antiinfl ammatory Th2 mediated secretion of IL4, IL5, IL13, and of the regulatory CD4+, CD25+ Foxp3 subpopulation. Treatment of EAE with 1,25(OH)2D stimulates the synthesis of IL4 and TGFβ1. Confl icting results have been reported on minor changes of Th2-mediated secretion of cytokines in the CNS and peripheral organs of the immune system after treatment with 1,25(OH)2D. 10, 12 Research on the causal link between the dynamics in serum concentrations of immune parameters, vitamin D levels and clinical indicators of disease activity will clarify aspects of the mechanism of the immune process so that the therapeutic control of disturbed immune regulation is optimized.
AIM
To evaluate changes in serum concentrations of IFN-gamma, IL17, TGFβ1, IL4, IL10, 25(OH)D in relapse and remission phases and their relationship with the degree of neurological defi cit.
INTRODUCTION
Multiple sclerosis (MS) is an immune disorder with multifactorial etiology, characterized by demyelination, axonal transection and oligodendropathy in the central nervous system (CNS). Data obtained in experimental allergic encephalomyelitis (EAE) support the thesis of CD4+ T cell-mediated destruction of the myelin with imbalance in cytokine secretion from Th1, Th17, Th2 lymphocyte subpopulations. In exacerbation the imbalance in the periphery is characterized by reduction of the regulatory CD4+, CD25+ Foxp3 subpopulation related to the production of the anti-infl ammatory cytokines TGFβ1, IL10, inhibited synthesis of IL4 and enhanced secretion of proinfl ammatory cytokines TNFα, IFN-gamma, IL17. 1,2 Clinical studies establish inconsistent results for cytokine secretion profi le in serum and cerebrospinal fl uid of patients during periods of relapse and remission when compared with controls. [3] [4] [5] The hypothesis of correlation between the pattern of myelin destruction, clinical manifestations, and potential therapeutic response is a reason to examine the involvement of various factors in the etiology and pathogenesis of MS. Extracorporeal vitamin D-factor prevents the development of EAE if administered before the induction with myelin protein and arrests the progress of the disease during treatment after the fi rst clinical signs. 6 Inclusion criteria -Caucasians community dwelling at 41°-42° northern latitude, aged 18-50 years; patients with relapsing-remitting MS, degree of neurological defi cit -1.5-5.0 after EDSS;
Exclusion criteria -primary and secondary progressive course; drug treatment modifying the disease course during the year preceding the date of registration; therapy with vitamin D and drugs affecting the metabolism of vitamin D (oral contraceptives, hormone replacement therapy, anti-epileptic agents, laxatives, thiazide diuretics), accompanying autoimmune diseases, acute and chronic infections, liver, kidney, and neoplastic diseases, hyperparathyroidism, diabetes, hypercalcaemia.
CONTROLS
Inclusion criteria -clinically healthy, age-and sex-matched subjects who were not on oral contraceptives, hormone replacement therapy, laxative preparations, or polyvitamins.
METHODS

Clinical methods: Diagnosis was made according to the McDonald criteria (2010)
. Neurological defi cit degree was assessed with the Expanded Disability Status Scale (EDSS, Kurtzke, 1983) . Relapse is defi ned as the onset of new neurological symptoms or worsening of old ones with duration >24 hours, aggravation of EDSS ≥ 0.5 degree in the absence of fever and after a period of 30-day improvement or stable condition after another relapse in succession.
Laboratory methods: Serum concentrations of cytokines IFN-gamma, IL17, TGFβ1, IL4, IL10 and 25-OH Vitamin D were determined by enzyme-linked immunosorbent analysis with original ELISA-kits, eBioscience, Austria, and original ELISA-kits, Immundiagnostik AG, Germany. Each sample was tested in duplicate analyses. Tests were serially read by ELISA-reader (Sirio-microplate reader, SEAC-Italy) at 450 nm (reference -620 nm).
STATISTICAL ANALYSIS
The number of observed objects was estimated at 5% α error and β error -20%. Quantitative indicators are presented as mean and standard error /± SEM/. Comparison of results between groups was performed using the independent sample t test and Mann-Whitney test at a signifi cance level of p < 0.05, depending on the results of the KolmogorovSmirnov test. Correlation analysis was also applied. For statistical data processing statistical software SPSS 17.0 was used.
RESULTS
The clinical characteristics of the participants is presented in Table 1 .
Comparison of mean age in patients and controls found no statistically signifi cant differences (p > 0.05, t = 1.316). All patients were registered by the end of the fi rst month of a consecutive relapse (between 3rd and 25th day), the highest proportion In remission the mean levels of IFN-gamma and IL17 tended to decrease compared to the levels in relapse. During both periods the mean concentrations of IFN-gamma were signifi cantly lower than those in controls (p = 0.036 in relapse, p = 0.005 in remission).
During remission mean concentrations of TGFβ1 increase statistically signifi cantly in comparison with exacerbation (p < 0.0001) and with controls (p < 0.001). The mean concentration of IL4 is signifi cantly lower in relapse than this in controls (p = 0.049), but in remission it tends to increase compared with exacerbation period (p = 0.054). No statistically signifi cant differences were found in the dynamics of IL10 in comparisons between patients and controls, relapse and remission. Analysis of mean serum concentrations of 25(OH)D between controls, patients in relapse and those in remission, did not fi nd any statistically signifi cant differences, but the established trends have to be mentioned. The mean levels in healthy subjects and patients were within the insuffi ciency range for Bulgarian population (25-49.99 nmol/l), most pronounced in patients with relapse (x ) ± SEM; healthy -31.46 ± 7.3; in relapse -26.93 ± 7.44; in remission -28.06 ± 7.28).
During remission average levels increase compared to those in relapse, but fail to reach statistical signifi cance. Results are presented in Fig. 1 .
Values for EDSS and 25(OH)D levels in relapse and remission are presented in Figure 2 . Correlation analysis (Spearman) found a negative correlation between the concentration of 25(OH)D in relapse and remission, and the degree of defi cit in both periods (r relapse = -0.593, р = 0.03; r remission = -0.46, р = 0.027). son with controls. Secretion of cytokine inducers of infl ammation -IFN-gamma, IL17 dominates during exacerbation. Various authors fi nd in patients in relapse signifi cantly higher secretion of IFN-gamma from peripheral blood mononuclear cells (PBMC), higher serum levels compared to remission. In brain lesions enhanced production of IFN-gamma, an inducer of oligodendrocyte apoptosis, is detected. 13, 14 We have found statistically signifi cant lower serum levels of IFN-gamma in patients in the two phases compared to controls. We assume that these data are related to the fl uctuation of anti-myelin reactivity. N. Hellings et al. fi nd transient increase in IFNgamma, TNFα, IL6 before exacerbation. In vitro studies confi rm these results. 4 Research on seasonal fl uctuations of cytokines reveals signifi cantly higher IFN-gamma levels in healthy individuals during winter than during summer. 15 We assume that the obtained results may refl ect such an aspect in the dynamics of cytokine secretion. The identifi ed tendency of decrease in serum concentrations of IL17 during remission compared to relapse is consistent with the results reported by V. Brucklacher-Waldert et al. for a signifi cantly higher proportion of IL17 lymphocytes during exacerbation compared to remission. 16 There has been experimental evidence proving an anti-infl ammatory potential of Th17 subpopulation. Results for the increase of mRNA levels in the infl ammation areas of the CNS are illustrative for elevated levels of IL17 in the serum and CSF of patients compared with controls. 5, 17, 18 No statistically signifi cant difference is found upon comparison of IL17 serum concentrations in patients and controls. Data of Kallaur A. et al. are similar. 5 We believe that signifi cantly increased levels of TGFβ1 during remission compared to relapse and controls is the result of enhanced secretion of TGFβ1 during this period and is an aspect of immune tolerance disorders in patients. Experimental data confi rm the regulatory function of TGFβ1 -retards the development of EAE, reduces the severity of clinical manifestations, suppresses reactivity of proinfl ammatory cytokines -TNFα, IFN-gamma, IL1, IL2, IL6. Clinical studies establish: negative correlation between serum concentrations of TGFβ1 and magnetic resonance activity; high TGFβ1mRNA levels in patients with low-degree neurological defi cit as opposed to those with severe defi ciency. 19 Studies on the secretion of IL4 and IL10 during both clinical periods report inconsistent results. We evaluate the tendency of increase in IL4 levels during remission compared with the relapse as an act of anti-infl ammatory mediator activity, confi rmed by experimental data: elevated levels of IL4 reduce the severity of EAE; antiIL4mAb treatment signifi cantly increased IFNgamma secreting cells. 5, 20 Similar to the results of this study are the data reported by C. Brandäo et al. 3 No correlation was detected between changes in the defi cit and serum concentrations of the cytokines during both clinical periods. We assume that the regulatory cytokine disbalance and EDSS scale refl ect with different specifi city the intensity of immune infl ammation. The degree of neurological defi cit is directly related to the loss of axons, but axonal damage have different mechanisms -immune-infl ammatory, degenerative, ischemic. In the group under observation unlike other observations no signifi cant differences were found in the dynamics of 25(OH)D levels in both periods and between patients and controls. 8, 9 The recorded signifi cant negative correlation between changes in the defi cit during the two phases and serum concentrations of 25(OH)D is established also by other authors. 25 
DISCUSSION
This study revealed persistent immune disbalance in patients during the two clinical periods in compari-
CONCLUSIONS
Persistent cytokine disbalance in patients compared to controls is indicative of Th1-mediated CNS demyelination. Anti-infl ammatory cytokines, TGFβ1, IL4 are indicators of the immune response intensity.
Neurological defi cit severity is not related to changes of the studied cytokines, but correlates negatively with changes in 25(OH)D serum levels during periods of relapse and remission.
